Template:SUIT text D006: Difference between revisions
From Bioblast
(Created page with "The SUIT-002 pfi D006 protocol in combination with SUIT-001_O2_pfi_D002 provides a common reference for comparison of respiratory control of [[permeabilized muscle fibers]...") |
Beno Marija (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
The SUIT-002 pfi D006 protocol in combination with [[SUIT-001_O2_pfi_D002]] provides a common reference for comparison of respiratory control of [[permeabilized muscle fibers]] in a wide variety of species and tissues. SUIT-002 pfi D006 is specially designed to give information on [[Fatty_acid_oxidation_pathway_control_state|F-pathway]] in [[Oxidative phosphorylation|OXPHOS state]] avoiding FAO overestimation in the presence of [[Anaplerosis|anaplerotic]] pathways. Moreover, the pathway control in OXPHOS state ([[Fatty_acid_oxidation_pathway_control_state|F]], F(N), [[FN]], [[FNS]], [[FNSGp]] pathways) and in [[ET | The SUIT-002 pfi D006 protocol in combination with [[SUIT-001_O2_pfi_D002]] provides a common reference for comparison of respiratory control of [[permeabilized muscle fibers]] in a wide variety of species and tissues. SUIT-002 pfi D006 is specially designed to give information on [[Fatty_acid_oxidation_pathway_control_state|F-pathway]] in [[Oxidative phosphorylation|OXPHOS state]] avoiding FAO overestimation in the presence of [[Anaplerosis|anaplerotic]] pathways. Moreover, the pathway control in OXPHOS state ([[Fatty_acid_oxidation_pathway_control_state|F]], F(N), [[FN]], [[FNS]], [[FNSGp]] pathways) and in [[ET capacity| ET state]] ([[FNSGp]] and [[SGp-pathway control state|SGp]]) can be evaluated by using this SUIT protocol. SUIT-002 pfi D006 can be extended with the CIV assay module. |
Revision as of 16:10, 8 June 2020
The SUIT-002 pfi D006 protocol in combination with SUIT-001_O2_pfi_D002 provides a common reference for comparison of respiratory control of permeabilized muscle fibers in a wide variety of species and tissues. SUIT-002 pfi D006 is specially designed to give information on F-pathway in OXPHOS state avoiding FAO overestimation in the presence of anaplerotic pathways. Moreover, the pathway control in OXPHOS state (F, F(N), FN, FNS, FNSGp pathways) and in ET state (FNSGp and SGp) can be evaluated by using this SUIT protocol. SUIT-002 pfi D006 can be extended with the CIV assay module.